Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa.

[1]  A. Baruchel,et al.  A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee) , 2016, Pediatric blood & cancer.

[2]  Y. Ebihara,et al.  Second allogeneic transplantation using unrelated cord blood for relapsed hematological malignancies after allogeneic transplantation , 2016, Leukemia & lymphoma.

[3]  N. Kröger,et al.  Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT , 2015, Bone Marrow Transplantation.

[4]  R. Krance,et al.  Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[6]  S. Devine,et al.  Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  J. Goldberg,et al.  Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts , 2015, Bone Marrow Transplantation.

[8]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  M. Norkin,et al.  Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  S. Meshinchi,et al.  AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia , 2014, Cancer.

[11]  W. Hiddemann,et al.  Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation , 2014, Bone Marrow Transplantation.

[12]  S. Theurich,et al.  Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. , 2014, The Cochrane database of systematic reviews.

[13]  N. Shukla,et al.  Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia , 2014, Pediatric blood & cancer.

[14]  P. Starostik,et al.  Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age. , 2013, Leukemia research.

[15]  N. Kröger,et al.  Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. L. Beau,et al.  A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes , 2013, Bone Marrow Transplantation.

[17]  B. Andersson,et al.  Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  C. Schmoor,et al.  Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML , 2013, Bone Marrow Transplantation.

[19]  F. Appelbaum,et al.  Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Labopin,et al.  Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT , 2012, Leukemia.

[21]  K. Kawa,et al.  Second allogeneic hematopoietic SCT for relapsed ALL in children , 2012, Bone Marrow Transplantation.

[22]  T. Alonzo,et al.  AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia. , 2009 .

[23]  M. Thakar,et al.  ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse? , 2009, Hematology. American Society of Hematology. Education Program.

[24]  J. Finke,et al.  A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation , 2008, Bone Marrow Transplantation.

[25]  M. Turner,et al.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  H. Lee,et al.  Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Management of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials , 2005 .

[27]  M. Tallman,et al.  Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant , 2004, Bone Marrow Transplantation.

[28]  W. Stock,et al.  Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant , 2001, Bone Marrow Transplantation.

[29]  M. Labopin,et al.  Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Cahn,et al.  Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de Moelle (SFGM) , 2000, British journal of haematology.

[31]  T. Lion,et al.  Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment , 1999, Leukemia.

[32]  S. Singhal,et al.  Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy , 1997, Bone Marrow Transplantation.

[33]  K. Kishi,et al.  Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes , 1997, Bone Marrow Transplantation.

[34]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[35]  M. Horowitz,et al.  Second HLA-identical sibling transplants for leukemia recurrence. , 1992, Bone marrow transplantation.

[36]  N. Flomenberg,et al.  New technology for the depletion of T cells from soybean lectin agglutinated, HLA-matched bone marrow grafts for leukemia: initial laboratory and clinical results. , 1992, Progress in clinical and biological research.

[37]  R. Storb,et al.  Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Grañena,et al.  Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases , 1988, British journal of haematology.

[39]  B. Dupont,et al.  Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. , 1983, Blood.